Status:
UNKNOWN
Effects of H.Pylori Eradication on Microbiome
Lead Sponsor:
University of Latvia
Collaborating Sponsors:
Latvian Biomedical Research and Study Centre
Conditions:
Human Microbiome
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
The aim of this Project is, within the scope of industrial research, to evaluate the long term effects of H.pylori eradication on microbiome (gut microbiome, upper respiratory tract microbiome) and la...
Detailed Description
The current international guidelines and expert working groups are encouraging "search-and-treat" strategy for H.pylori to prevent gastric cancer1, 2. The highest yield of this approach is expected in...
Eligibility Criteria
Inclusion
- Individuals with established H.pylori infection
- Individuals in whom H.pylori eradication therapy is indicated according to the international or national recommendations
- Individuals who agree to undergo H.pylori eradication therapy
Exclusion
- Severely sick patients
- Individuals in whom H.pylori eradication therapy is contra-indicated due to any reasons
- Individuals unable or unwilling to provide a sample for microbiome testing
Key Trial Info
Start Date :
July 29 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT03231332
Start Date
July 29 2017
End Date
December 31 2025
Last Update
August 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Latvia
Riga, Latvia, LV 1586